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Plasmodium falciparum HRP2 ELISA
for analysis of dried blood spot samples
in rural Zambia
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Philip E. Thuma3 and David W. Wright1*

Abstract
Background: Dried blood spots are commonly used for sample collection in clinical and non-clinical settings. This
method is simple, and biomolecules in the samples remain stable for months at room temperature. In the field, blood
samples for the study and diagnosis of malaria are often collected on dried blood spot cards, so development of a
biomarker extraction and analysis method is needed.
Methods: A simple extraction procedure for the malarial biomarker Plasmodium falciparum histidine-rich protein 2
(HRP2) from dried blood spots was optimized to achieve maximum extraction efficiency. This method was used to
assess the stability of HRP2 in dried blood spots. Furthermore, 328 patient samples made available from rural Zambia
were analysed for HRP2 using the developed method. These samples were collected at the initial administration of
artemisinin-based combination therapy and at several points following treatment.
Results: An average extraction efficiency of 70% HRP2 with a low picomolar detection limit was achieved. In specific
storage conditions HRP2 was found to be stable in dried blood spots for at least 6 months. Analysis of patient samples
showed the method to have a sensitivity of 94% and a specificity of 89% when compared with microscopy, and
trends in HRP2 clearance after treatment were observed.
Conclusions: The dried blood spot ELISA for HRP2 was found to be sensitive, specific and accurate. The method was
effectively used to assess biomarker clearance characteristics in patient samples, which prove it to be ideal for gaining
further insight into the disease and epidemiological applications.
Keywords: Dried blood spots, ELISA, Malaria, Plasmodium falciparum histidine-rich protein 2, Biomarker clearance
Background
Sample collection is a major challenge for disease diagnosis in non-clinical settings. In low-resource areas, the
collection of venous blood is not always feasible, so blood
samples are often collected via finger prick and stored
on filter paper cards. These samples, called dried blood
spots (DBS), result in increased biomolecule sample stability compared to liquid samples, as they can be stored
in ambient conditions. Additionally, DBS samples have a
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low biohazard risk and thus can be easily shipped [1, 2].
These advantages have led to the commercial availability of several types of DBS collection cards with different features including easy labelling and incorporation of
reagents for blood lysis or biomarker stability [3].
Dried blood spot samples have proven useful for
the analysis of a variety of markers including proteins,
nucleic acids, and drugs. Methods employing DBS
require an extraction procedure followed by techniques
such as ELISA or PCR to analyse the extracted samples
[4]. For example, detection of hepatitis C, a measles specific antibody, and Streptococcus pneumoniae from DBS
samples were shown to be reliable when validated against
gold standards for detection [5–7]. Additionally, dried
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blood spots are extensively used in newborn screening
programmes which test for congenital disorders including those that are metabolic, such as hyperthyroidism,
and those that are genetic, such as cystic fibrosis [8–10].
Malaria, a parasitic disease transmitted through mosquitoes, caused 212 million infections in 2015. A majority of these cases occurred in Africa, where access to
clinical laboratories is limited [11]. Malaria is regularly diagnosed with rapid diagnostic tests (RDTs) that
detect Plasmodium falciparum histidine-rich protein 2
(HRP2), a uniquely structured and highly stable protein
biomarker [12]. In this work, a method for the extraction of HRP2 from dried blood spots was optimized.
Various parameters were explored including extraction
buffer, mixing method and extraction time. Additionally, the percent recovery of HRP2 and the biomarker
stability were studied. Following extraction, a previously
developed HRP2 ELISA was used for biomarker quantification [13]. This ELISA can detect low-level or asymptomatic infections that may otherwise be undetectable, and
its high-throughput nature is useful for epidemiological
studies [14]. The coupling of the optimized extraction
method with this ELISA allowed for detection of HRP2
from DBS; a procedure that was then used to test patient
samples in rural Zambia. This study allowed for determination of the method sensitivity, specificity and reproducibility, as well as biomarker clearance characteristics.

Plasmodium falciparum histidine‑rich protein 2 ELISA
protocol

Methods

Dried blood spot Plasmodium falciparum histidine‑rich
protein 2 ELISA

Materials

Human Whole Blood (K3 EDTA) was purchased from
Bioreclamation IVT (Catalog No. HMWBEDTA3).
Plasmodium falciparum D6 parasite was cultured in
house. Recombinant HRP2 protein (rc-HRP2) for traditional ELISA standard curve was purchased from
Immunology Consultants Laboratory Inc. (Catalog No.
AGPF-55). ELISA capture and detection antibodies
were acquired from Abcam Inc. (Catalog Nos. ab9206
and ab30384). Immulon 2HB ELISA plates (Catalog No. 14-245-61) and TMB One ELISA substrate
(Catalog No. PR-G7431) were purchased from Fisher
Scientific. 903 Protein Saver cards and Whatman 3
filter paper, were purchased from GE Healthcare Life
Sciences (Catalog Nos. 10534612 and 1003-055). Biopunches, 6 mm, were acquired from Ted Pella Inc.
(Catalog No. 15111-60). All other reagents were purchased from either Fisher Scientific or Sigma Aldrich.
DBS extraction was performed with a Fisher Scientific Analog Vortex Mixer (Catalog No. 02-215-365).
Absorbance measurements were collected on a Biotek
Synergy H4 microplate reader (Vanderbilt University)
or Biotek ELx808 microplate reader (Macha Research
Trust).

The HRP2 ELISA protocol has been previously reported
[13]. Briefly, 1 µg/mL of anti-HRP2 IgM (ab9206) in PBS
was immobilized for 1 h in an Immulon 96-well plate,
which was then blocked with 5% BSA in PBST (1× PBS,
0.1% Tween-20) for 2 h. Samples were then diluted in
sample buffer (PBST, 0.1% BSA) and added to the plate
for 2 h. Finally, horseradish peroxidase conjugated detection antibody (ab30384) was added at 0.5 µg/mL in PBST
with 0.5% BSA for 1 h. Signal was visualized with TMBOne, a commercially available 3,3′,5,5′-tetramethylbenzidine (TMB) substrate and stopped with 2 M sulfuric acid
after 10 min. Absorbance was read at 450 nm.
Dried blood spot extraction

DBS were prepared by spiking P. falciparum D6 parasite
culture into whole blood and spotting 10 μL onto Whatman 903 Protein Saver cards (903 cards) or Whatman 3
filter paper (W3). Extraction was performed on 6 mm
spots. Two spots were extracted for each sample, in one,
2-mL microcentrifuge tube with 300 µL PBST extraction buffer. The tubes were vortexed at maximum speed
(3200 rpm) for 10 min. Afterwards, tubes were centrifuged to remove bubbles and spin down the DBS paper.
The supernatant was then removed and analysed by
ELISA.

The previously reported HRP2 ELISA [13] was performed with the following modifications: (1) The standard curve was made from DBS standards to incorporate
extraction conditions into the standard curve, (2) samples were directly added to the plate in the PBST extraction buffer instead of being diluted in sample buffer.
Percent recovery calculation

Percent recovery was determined by comparing ELISA
signal from a blank (whole blood diluted 1:14 in PBST)
and a positive control (whole blood spiked with parasite
to 200 parasites/µL, diluted 1:14 in PBST) to ELISA signal from an extracted DBS sample. For example, percent
recovery for a 200 parasites/µL DBS sample was calculated using the following equation:


ADBS − Ablank
× 100
% Recovery HRP2 =
Apositive − Ablank
Stability study

Dried blood spots were prepared on 903 cards and W3.
The spots were stored in Ziploc bags containing desiccant at the following temperatures: room temperature
(RT), 4, −20 and −80 °C. Samples were stored for various
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lengths of time, extending up to 6 months, and analysed
for percent recovery of HRP2.
Study setting

Patient samples were collected during a separate study
carried out in the Nchelenge District of Zambia, an
area where malaria transmission has been sustained
at a high level despite interventions [15]. The original
study was designed to determine parasite clearance rates
after treatment with artemisinin-based combination
therapy (ACT) in children under 5 years of age presenting with uncomplicated malaria to the local clinic. The
anonymized samples were made available for the current
study to determine if HRP2 clearance could be used as a
proxy for parasite clearance rates.
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removed for analysis by HRP2 ELISA with two modifications: (1) the standard curve (0–20 parasites/µL) was
made from D6 parasite culture spiked into 1:29 (v:v)
whole blood in PBST to approximate DBS extract matrix,
and (2) after extraction, the samples were diluted tenfold
in PBST before addition to the plate.
Sample size calculation

Appropriate sample size is essential for validation of diagnostic tests. Buderer reported an equation for calculation
of sample size to ensure that a planned study would have
sufficient power [16, 17]. This number is dependent on
estimated sensitivity or specificity, and equations for each
are shown below. To ensure sufficient sample size, the
larger of the two was chosen.

Patient recruitment and ethics

Children who arrived at the clinic and tested positive for
malaria according to SD Bioline HRP2 malaria RDTs were
recruited for this study after the parent or guardian provided signed informed consent. The study and samples
were collected under IRB approval TDRC/C4/09/2014
as well as after approval was granted by the Zambian
National Health Research Authority (MH/101/17/6).
Patient samples

Patient finger-prick blood samples were collected on
903 cards between December 2014 and August 2015.
DBS HRP2 ELISA analysis was done in July 2016. In
the interim between collection and analysis, the DBS
samples were stored at −20 °C. At the time of collection, finger-prick samples were analysed by thick smear
microscopy to determine quantitative parasite levels by
counting parasites per 200 white blood cells and then
using an estimate of 8000 WBC/μL to obtain the parasite count for that particular time point. This analysis was
used as the gold standard in this study. After diagnosis
by RDT and P. falciparum parasitaemia confirmation by
a malaria smear, patients were enrolled and treated with
artemether–lumefantrine (Coartem®). Thick blood film
malaria smears and DBS samples were collected at 15
time points: 0, 6, 12, 18, 24, 30, 36, 42, and 48 h and days
3, 7, 14, 21, 28, and 35. In the current study, samples from
time points 0, 6, 12 and 18 h as well as days 28 and/or 35
were made available and analysed for 35 patients. Additionally, all 15 time points were studied for 10 patients.

nSe =

Z 2α Se(1 − Se)
2

d 2 × Prev

nSp =

Z 2α Sp(1 − Sp)
2

d 2 × (1 − Prev)

Variables are defined as: n = number of samples,
Se = sensitivity, Sp = specificity, Z = Z score (1.96 for
this analysis), d = confidence interval, and Prev = prevalence of disease. For this study, we chose d = 0.1. For this
analysis, the prevalence was approximated at 70% and
the desired sensitivity and specificity were 90 and 80%
respectively. When these values were incorporated into
the above equation, nSe = 49 samples and nSp = 205 samples. A sufficient sample size of 238 DBS was analysed.
Data analysis

For DBS samples, the concentration of HRP2 extracted
was determined via standard curves. For the standard
D6 parasite culture, 1 parasite/µL = 1.7 pM HRP2 (see
Additional file 1: Figure S1). All error bars shown in the
data represent the standard deviation between replicates
of the samples analysed. Intra-assay variability was calculated by finding the standard deviation of replicates run
at a single concentration, in a single assay, and dividing
by the mean of the replicates. Inter-assay variability was
found by determining the standard deviation of a single
concentration for assays run on different days and dividing by the mean value for that concentration. The sensitivity and specificity of the DBS HRP2 ELISA method
was determined through a ROC curve analysis using
microscopy results as the gold standard.

Results

Patient sample dried blood spot ELISA

Optimization of extraction parameters

Before analysis, patient samples were coded to ensure
assays were performed blinded to microscopy results.
To begin, one, 6-mm DBS spot was placed in a 2 mL
microcentrifuge tube with 300 µL of PBST extraction
buffer. After vortexing for 10 min, the supernatants were

In order to analyse HRP2 in a DBS sample, the extraction method had to be optimized. The technique used
for mixing was chosen by extraction into PBST using
rotisserie, vortex, and sonicator mixing as well as without mixing. It was found that recovery of HRP2 increased
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as the energy imparted by the mixing method increased
(Fig. 1a). Vortex mixing was selected as it resulted in a
high recovery and is also feasible in low resource settings
[18]. No difference in recovery was seen between 10 and
30 min of mixing (see Additional file 1: Figure S2).
Extraction buffer compositions with varying salt concentrations and lysis reagents were also explored. The
composition of the buffers analysed are listed in Additional file 1: Table S1. A greater percent recovery of HRP2
was observed with buffers which contained nonionic surfactants, likely due to greater solubilization of the protein
by the long polyethylene glycol chains. Salt concentration
did not affect recovery (Fig. 1b). PBST (Buffer 1) was chosen as the extraction buffer.
The ratio of extraction buffer to 6 mm DBS was also
examined for impact on HRP2 recovery. Our study
showed no significant difference in recovery for volumes
of 150–250 µL per 6 mm DBS (see Additional file 1: Figure S3). Similarly it was found that extracting two, 6 mm
DBS in 300 µL of buffer compared to one, 6 mm DBS
doubled the slope of the standard curve, increasing assay
sensitivity (see Additional file 1: Figure S4).
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Finally, the effect of heating was analysed by placing
DBS in extraction buffer and then in a heat block at 40, 60
and 80 °C for 10 min. The samples were then vortexed for
10 min before analysis by ELISA. Heating at 60 °C increased
recovery of HRP2 from approximately 70% to 90% (Fig. 1c).
For this method, room temperature was chosen to reduce
necessary instrumentation, but a heating step can be added
if increased assay sensitivity is required.
Dried blood spot card type and Plasmodium falciparum
histidine‑rich protein 2 recovery and stability

903 cards are designed for DBS collection while W3 is
made for filtration. Because 903 cards are more expensive than W3, many field studies with limited budgets
have employed W3. To determine if the paper type has an
effect on HRP2 recovery, DBS samples were prepared on
each card type. It was found that recovery of HRP2 from
903 cards was consistently 20% greater than recovery
from samples on W3 (Fig. 1d). HRP2 stability was also
assessed with both card types. It was observed that HRP2
was less stable in W3 samples with only 30% of the initial HRP2 recovery observed after being stored at room

Fig. 1 Optimization of parameters for the extraction of Plasmodium falciparum histidine-rich protein 2 (HRP2) from dried blood spot (DBS) samples.
a Mixing method, b extraction buffer, c temperature and d dried blood spot card type

Gibson et al. Malar J (2017) 16:350

temperature for 6 months. Samples on 903 cards retained
50% of the initial recovery after being stored for 6 months
at room temperature. Additionally, samples on 903 cards
retained 100% of the original recovery after storage for
6 months at −20 and −80 °C (Fig. 2).
Comparison to traditional Plasmodium falciparum
histidine‑rich protein 2 ELISA

Using the optimized protocol for extraction of two,
6 mm DBS in 300 µL of PBST, with vortex mixing for
10 min, standard curves were generated from parasitespiked DBS samples on 903 cards. The resulting curves
were highly reproducible with an intra-assay variability
of 7% and inter-assay variability of 10% (n = 3) (Fig. 3).
The limit of detection (LOD), defined as 3σblank/slope,
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was 4 ± 5 parasites/µL (8 ± 8 pM HRP2). Samples were
then analysed simultaneously on the previously reported
HRP2 ELISA and the DBS HRP2 ELISA [13]. Upon analysis with a paired t test, all p values were greater than
0.05 proving there was no statistical difference between
the HRP2 levels found by the two methods (Fig. 3).
Analysis of patient samples from rural Zambia

The standard curves used for analysis of DBS patient
samples were made from parasite-spiked diluted whole
blood. These assays, performed at Macha Research Trust,
had an intra-assay variability of 6% and an inter-assay variability of 18% (n = 14). The LOD determined by 3σblank/
slope was 0.165 ± 0.003 pM HRP2 (see Additional file 1:
Figure S5). 238 DBS patient samples collected within 24 h

Fig. 2 The stability of Plasmodium falciparum histidine-rich protein 2 (HRP2) in dried blood spots, over time, in different storage conditions. Stability
on 903 Protein Saver cards (left) and Whatman 3 filter paper (right)

Fig. 3 The reproducibility and accuracy of the developed dried blood spot (DBS) Plasmodium falciparum histidine-rich protein 2 (HRP2) ELISA. DBS
standard curves run on three different days (left) and comparison of HRP2 values between the DBS ELISA and a traditional ELISA (right)
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or at least 28 days after malaria diagnosis and treatment
were analysed by DBS HRP2 ELISA (see Additional file 1:
Table S2). Using microscopy as the gold standard, a ROC
curve was used to determine the sensitivity and specificity of the assay. It was found to have sensitivity of 94% (CI
89–97%) and specificity of 89% (CI 79–95%) when the
threshold was set at 3.5 pM HRP2 (Fig. 4). The area under
the ROC curve was 0.96, indicating excellent accuracy of
the method. Furthermore, using this threshold, the positive predictive value (PPV) for the assay was 95% and the
negative predictive value (NPV) was 86%.
Plasmodium falciparum histidine‑rich protein 2 clearance

For 10 patients, all 15 time points were analysed and used
to study the clearance of parasite and HRP2 after treatment (Fig. 5; Additional file 1: Figure S6). For these ten
patients, the median clearance time of the parasite was
1.38 days (0.5–3 days). For HRP2, two patients were
HRP2 negative by the ELISA at all time points, so they
were excluded from the median calculation. The median
clearance time of HRP2 for the remaining eight patients
was 5 days (0.25–21 days). Various HRP2 clearance
trends were observed when looking at each patient individually. As mentioned previously, two patients with low
initial parasitaemias (see Additional file 1: Figure S6C, F),
were negative for HRP2 according to the 3.5 pM threshold. Patient 51 (see Additional file 1: Figure S6E) had relatively low HRP2 levels before a large spike at t = 1 day.
Patients 25, 27 and 45 (Fig. 5a; Additional file 1: Figure
S6A, B, respectively) all showed HRP2 levels which corresponded with parasite load but with a lag in clearance
time. Patients 49 (see Additional file 1: Figure S6D) and
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50 (Fig. 5b) displayed the same trend except for a couple
of spikes corresponding to a decrease in parasite levels.
The HRP2 level in Patient 43 (Fig. 5c) spiked and fell
throughout the study but was cleared by the last time
point. Finally, Patient 44 (Fig. 5d) showed decreasing
HRP2 levels over time until they began to rise at the last
three time points while parasite levels remained negative.
To ascertain whether there was a correlation between
parasite and HRP2 levels, the DBS HRP2 ELISA results
for all 328 patient samples were compared to microscopy.
A positive, linear association was observed, with a Spearman correlation coefficient (ρ) equal to 0.70 (95% CI
0.63–0.75, p < 0.0001) (Fig. 6).

Discussion
Plasmodium falciparum histidine‑rich protein 2 and dried
blood spots

Extraction of HRP2 from DBS was achieved reproducibly, but several factors affected its efficiency, including
the type of paper on which the DBS was prepared. This is
an important variable to consider, as 903 cards cost up to
eight times more than W3. As shown in the results section, 903 cards had up to a 20% greater recovery of HRP2,
and HRP2 did not degrade in these cards when stored
frozen for 6 months (Figs. 1d, 2). These results indicate
that although the more cost effective alternative is often
chosen in field study design, in this case the additional
cost enhances performance. The authors conclude that
903 cards most likely provide a more stable matrix for
protein storage, and their increased thickness allows for
a greater volume of blood in a specific DBS area resulting
in greater protein recovery.
ROC curve analysis

Fig. 4 ROC curve for dried blood spot (DBS) Plasmodium falciparum
histidine-rich protein 2 (HRP2) ELISA when compared to clinical
microscopy values for patient samples from rural Zambia. Sensitivity of the assay was 94% (CI 89–97%) and specificity was 89% (CI
79–95%) when the threshold was set at 3.5 pM HRP2

ROC curves are used as a metric to determine the sensitivity and specificity of a diagnostic assay as compared
to the chosen gold standard. An ideal ROC curve forms
a 90º angle in the left corner of the graph, which corresponds to a test with 100% sensitivity and 100% specificity. In this analysis, the DBS HRP2 ELISA was found
to have a sensitivity of 94% and a specificity of 89% with
a threshold of 3.5 pM HRP2 (Fig. 4). This result demonstrates the developed DBS HRP2 ELISA is a reliable
diagnostic for malaria. Reduced specificity compared
to sensitivity can be attributed to the fact that the gold
standard for malaria diagnosis (microscopy) detects
the malaria parasite rather than the protein biomarker
detected with the DBS HRP2 ELISA. This discrepancy
can result in false positives by DBS ELISA, because HRP2
can persist in the blood stream days to weeks after parasite clearance [19, 20]. Furthermore, microscopy has
shortcomings of its own, including a lack of sensitivity.
In general, ELISA is more sensitive than microscopy [21].

Gibson et al. Malar J (2017) 16:350
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Fig. 5 Representative data of different Plasmodium falciparum histidine-rich protein 2 (HRP2) clearance trends that were observed in patient
samples collected at 15 time points, over a 35-day period. The concentration of HRP2 extracted from the dried blood spot (DBS) samples and the
parasitaemia determined by microscopy are plotted against time. a Patient 27, b Patient 50, c Patient 43 and d Patient 44

As a result, false positives could result from the ability of
the DBS HRP2 ELISA to detect malaria infections that
are not seen by microscopy.
While a lower threshold would allow for detection of
more truly HRP2-positive samples, it would also result
in detection of residual HRP2 that is not the result of an
active malaria infection. This observation points to a disadvantage of HRP2 as a biomarker, as its persistence can
result in misdiagnosis of patients and improper treatment
[22]. To address this issue, an alternative protein biomarker that quickly clears from the bloodstream, Plasmodium lactate dehydrogenase (pLDH), is being further
explored in our lab [20, 23]. Nonetheless, the importance
of detection of HRP2 remains, as it continues to be the
most sensitive and prevalently used protein biomarker
for detection of falciparum malaria infections [12].
Biomarker clearance

Several different trends were observed in the clearance
patterns of HRP2, indicating that the response of each
patient to the disease is different. Despite this, some
similarities were observed, including delayed HRP2
clearance compared to parasite clearance, a result of the

persistence of HRP2 [24]. Additionally, the spikes seen in
several patients directly after a decrease in parasite load
are likely caused by the release of HRP2 upon parasite
death [25]. Finally, in one patient, HRP2 levels increased
in the final time points indicating reinfection or recrudescence may have occurred (Fig. 5d). Reinfection is when
an individual is successfully treated for malaria but then
becomes sick again with an entirely new malaria infection [26]. Recrudescence occurs when the same malaria
infection is never fully eliminated by treatment and reappears [27]. Without sample genotyping the cause of the
HRP2 spike in this sample cannot be confirmed [28, 29].
Using the ROC curve threshold, information can be
gathered about infection levels and HRP2 persistence
in the blood. For this study, infections levels were classified as follows: low (0–14,999 parasites/µL), medium
(15,000–75,000 parasites/µL) and high (≥75,000 parasites/µL). Besides the case discussed above, Patients 3
and 37 (see Additional file 1: Table S2) had HRP2 levels
that were positive at the end of the time study meaning these samples contained HRP2 as long as 30 days
after the beginning of treatment. Furthermore, samples
from Patients 43 and 45 (Fig. 5c; Additional file 1: Figure
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sample. Additionally, the amount of HRP2 produced by
the parasite is dependent on the life stage and strain [25,
34]. Patient samples have much greater variety in these
parameters than parasite culture, resulting in a weaker
association between HRP2 and parasite levels. Other literature reports have seen similar discrepancies in patient
samples, as some report correlation between HRP2 levels
and disease severity, while others do not [35, 36]. Nonetheless, in this work a positive association between HRP2
and parasite levels was observed, indicating the usefulness of the HRP2 biomarker in malaria diagnosis.

Fig. 6 Correlation between parasite and HRP2 levels that were
observed in the 328 patient samples from rural Zambia. Spearman
correlation coefficient (ρ) = 0.70 (95% CI 0.63–0.75, p < 0.0001)

S6B, respectively), which were analysed for the full time
study, retained HRP2 past the median time-to-clearance of 5 days. It could be expected that these extended
clearance times were a result of high level infections
but instead it was found that the initial parasite level
for each of these patients was below 25,000 parasites/
µL. This result suggests that persistence of HRP2 was a
result of chronic infections. In chronic infections, lowlevel parasitaemias can persist in a patient for years,
with minimal symptoms, and then become symptomatic [30–32]. The longevity of the infection can allow
for build-up of HRP2 over time, so even though the parasite load is low, a significant amount of HRP2 persists
in the blood.
Association between parasite and biomarker levels

A correlation between parasite and HRP2 levels measured by microscopy and DBS HRP2 ELISA respectively
was observed (Fig. 6). The Spearman correlation coefficient (ρ) was 0.70, and this result statistically proves
an association between these two variables. The
strength of the association is considered to be moderate (ρ = 0.5–0.7) to high (ρ = 0.7–0.9) [33]. As can be
seen in Additional file 1: Figure S1, in the case of parasite culture this correlation between HRP2 and parasite
levels is direct. Several different factors could have contributed to the decrease in the strength of association
observed with patient samples. For example, the lack of
strictly controlled storage conditions for the DBS samples likely caused protein degradation and variability
in extraction efficiency. As a result, in the analysis of
the patient samples there were other influences on protein recovery besides the initial parasitaemia of the

Conclusions
Dried blood spots represent a common and simple
sample collection method for clinical and non-clinical
settings. Samples stored in this way are stable and easily shipped. In order to analyse these samples, methods
must be optimized for extraction of a specific biomarker
and subsequent analysis. This is a report of a highly
reproducible procedure for extraction of the malarial biomarker HRP2 and subsequent analysis of the protein by
ELISA. This assay was then used to analyse patient samples in rural Zambia and was found to have a 94% sensitivity and 89% specificity. Examination of patient samples
also revealed trends in biomarker clearance, showing
sustained HRP2 in the blood. Furthermore, a positive,
linear association between parasite and HRP2 levels was
observed. Thus, the reported method is reliable for detection of malaria from commonly collected dried blood
spot samples and can be applied further in epidemiological studies and to assist in the development of improved
diagnostics through increased understanding of disease
characteristics.
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Additional file 1. Additional data from optimization of dried blood spot
extraction. Reproducibility of the standard curves performed at Macha
Research Trust. Dried blood spot ELISA results for patient samples and
additional time study data. Figure S1. Amount of HRP2 in D6 parasite
culture. Figure S2. Mixing time. Table S1. Extraction buffer compositions. Figure S3. Extraction buffer volume. Figure S4. Number of dried
blood spots and assay sensitivity. Figure S5. Standard curves from Macha
Research Trust. Table S2. Additional patient sample data. Figure S6.
Additional time study data.
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